Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19

The present Perspective examined the latest evidence on the association between the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID‐19). Our critical appraisal from existing literature does...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Martin C.S., Wong, Sunny, Huang, Junjie, Yan, Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524232/
https://www.ncbi.nlm.nih.gov/pubmed/33121220
http://dx.doi.org/10.1002/ehf2.12952
_version_ 1783588517936365568
author Wong, Martin C.S.
Wong, Sunny
Huang, Junjie
Yan, Bryan
author_facet Wong, Martin C.S.
Wong, Sunny
Huang, Junjie
Yan, Bryan
author_sort Wong, Martin C.S.
collection PubMed
description The present Perspective examined the latest evidence on the association between the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID‐19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice‐changing guidelines.
format Online
Article
Text
id pubmed-7524232
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75242322020-10-02 Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19 Wong, Martin C.S. Wong, Sunny Huang, Junjie Yan, Bryan ESC Heart Fail Perspective The present Perspective examined the latest evidence on the association between the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the incidence/mortality of coronavirus disease 2019 (COVID‐19). Our critical appraisal from existing literature does not support discontinuation of ACEIs/ARBs in clinical practice as there is absence of solid evidence. However, we do recommend future research perspective in formulation and implementation of practice‐changing guidelines. John Wiley and Sons Inc. 2020-07-28 /pmc/articles/PMC7524232/ /pubmed/33121220 http://dx.doi.org/10.1002/ehf2.12952 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Perspective
Wong, Martin C.S.
Wong, Sunny
Huang, Junjie
Yan, Bryan
Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title_full Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title_fullStr Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title_full_unstemmed Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title_short Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
title_sort relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of covid‐19
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524232/
https://www.ncbi.nlm.nih.gov/pubmed/33121220
http://dx.doi.org/10.1002/ehf2.12952
work_keys_str_mv AT wongmartincs relatingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockerswithincidenceormortalityofcovid19
AT wongsunny relatingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockerswithincidenceormortalityofcovid19
AT huangjunjie relatingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockerswithincidenceormortalityofcovid19
AT yanbryan relatingangiotensinconvertingenzymeinhibitorsorangiotensinreceptorblockerswithincidenceormortalityofcovid19

Ejemplares similares